T. Rowe Price Associates’s Amylyx Pharmaceuticals AMLX Stock Holding History

T. Rowe Price Associates’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.69M	Buy	121,439 +13,891	+13%	+$195K	﹤0.01%	1905
2025 Q4	$1.3M	Buy	107,548 +7,103	+7%	+$96.5K	﹤0.01%	1966
2025 Q3	$1.37M	Buy	100,445 +9,053	+10%	+$85.2K	﹤0.01%	1917
2025 Q2	$586K	Buy	91,392 +33,692	+58%	+$164K	﹤0.01%	2231
2025 Q1	$205K	Hold	57,700	–	–	﹤0.01%	2618
2024 Q4	$219K	Buy	57,700 +2,100	+4%	+$9.88K	﹤0.01%	2640
2024 Q3	$181K	Hold	55,600	–	–	﹤0.01%	2686
2024 Q2	$106K	Sell	55,600 -914,955	-94%	-$1.77M	﹤0.01%	2752
2024 Q1	$2.76M	Buy	970,555 +75,775	+8%	+$991K	﹤0.01%	1428
2023 Q4	$13.2M	Buy	894,780 +870,560	+3,594%	+$13.3M	﹤0.01%	1042
2023 Q3	$444K	Buy	24,220 +1,132	+5%	+$23.9K	﹤0.01%	2163
2023 Q2	$499K	Buy	23,088 +581	+3%	+$15.7K	﹤0.01%	2135
2023 Q1	$661K	Buy	22,507 +6,824	+44%	+$237K	﹤0.01%	1989
2022 Q4	$579K	Buy	+15,683	New	+$557K	﹤0.01%	2070

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

T. Rowe Price Associates's AMLX Position: Q1 2026 in Review

T. Rowe Price Associates increased its Amylyx Pharmaceuticals (AMLX) stake by 13% in Q1 2026, buying an estimated $195K and bringing the position to 121,439 shares worth $1.69M. The position accounts for ﹤0.01% of the portfolio, ranked #1905.

T. Rowe Price Associates first reported a position in AMLX in Q4 2022 and has held it in 14 quarters since. The position peaked at $13.2M in Q4 2023. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

T. Rowe Price Associates held 121,439 shares of Amylyx Pharmaceuticals worth $1.69M as of Q1 2026.
T. Rowe Price Associates bought 13,891 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $195K.
Amylyx Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1905 holding.
T. Rowe Price Associates first reported a position in Amylyx Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
T. Rowe Price Associates's Amylyx Pharmaceuticals position peaked at $13.2M in Q4 2023.
171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.